Literature DB >> 31201995

Antimicrobial susceptibility testing and antibiotic consumption results from 16 hospitals in Viet Nam: The VINARES project 2012-2013.

Tien Viet Dung Vu1, Thi Thuy Nga Do2, Ulf Rydell3, Lennart E Nilsson4, Linus Olson5, Mattias Larsson6, Håkan Hanberger7, Marc Choisy8, Tuyet Trinh Dao9, H Rogier van Doorn2, Van Kinh Nguyen9, Vu Trung Nguyen9, Heiman F L Wertheim10.   

Abstract

OBJECTIVE: To establish a hospital-based surveillance network with national coverage for antimicrobial resistance (AMR) and antibiotic consumption in Viet Nam.
METHODS: A 16-hospital network (Viet Nam Resistance: VINARES) was established and consisted of national and provincial-level hospitals across the country. Antimicrobial susceptibility testing results from routine clinical diagnostic specimens and antibiotic consumption data in Defined Daily Dose per 1000 bed days (DDD/1000 patient-days) were prospectively collected and analysed between October 2012 and September 2013.
RESULTS: Data from a total of 24 732 de-duplicated clinical isolates were reported. The most common bacteria were: Escherichia coli (4437 isolates, 18%), Klebsiella spp. (3290 isolates, 13%) and Acinetobacter spp. (2895 isolates, 12%). The hospital average antibiotic consumption was 918 DDD/1000 patient-days. Third-generation cephalosporins were the most frequently used antibiotic class (223 DDD/1000 patient-days, 24%), followed by fluoroquinolones (151 DDD/1000 patient-days, 16%) and second-generation cephalosporins (112 DDD/1000 patient-days, 12%). Proportions of antibiotic resistance were high: 1098/1580 (69%) Staphylococcus aureus isolates were methicillin-resistant (MRSA); 115/344 isolates (33%) and 90/358 (25%) Streptococcus pneumoniae had reduced susceptibility to penicillin and ceftriaxone, respectively. A total of 180/2977 (6%) E. coli and 242/1526 (16%) Klebsiella pneumoniae were resistant to imipenem, respectively; 602/1826 (33%) Pseudomonas aeruginosa were resistant to ceftazidime and 578/1765 (33%) to imipenem. Of Acinetobacter spp. 1495/2138 (70%) were resistant to carbapenems and 2/333 (1%) to colistin.
CONCLUSIONS: These data are valuable in providing a baseline for AMR among common bacterial pathogens in Vietnamese hospitals and to assess the impact of interventions.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Defined daily dose (DDD)/1000 patient-days; Hospital-based surveillance; Surveillance; Viet Nam

Mesh:

Substances:

Year:  2019        PMID: 31201995     DOI: 10.1016/j.jgar.2019.06.002

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  9 in total

Review 1.  Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries.

Authors:  Sumanth Gandra; Gerardo Alvarez-Uria; Paul Turner; Jyoti Joshi; Direk Limmathurotsakul; H Rogier van Doorn
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017.

Authors:  Tien Viet Dung Vu; Marc Choisy; Thi Thuy Nga Do; Van Minh Hoang Nguyen; James I Campbell; Thi Hoi Le; Vu Trung Nguyen; Heiman F L Wertheim; Ngoc Thach Pham; Van Kinh Nguyen; H Rogier van Doorn
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-10       Impact factor: 4.887

3.  Purchase and use of antimicrobials in the hospital sector of Vietnam, a lower middle-income country with an emerging pharmaceuticals market.

Authors:  Vu Quoc Dat; Phan Khanh Toan; H Rogier van Doorn; C Louise Thwaites; Behzad Nadjm
Journal:  PLoS One       Date:  2020-10-20       Impact factor: 3.240

Review 4.  Epidemiology of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Enterobacterales in the Greater Mekong Subregion: A Systematic-Review and Meta-Analysis of Risk Factors Associated With Extended-Spectrum Beta-Lactamase and Carbapenemase Isolation.

Authors:  Shweta R Singh; Alvin Kuo Jing Teo; Kiesha Prem; Rick Twee-Hee Ong; Elizabeth A Ashley; H Rogier van Doorn; Direk Limmathurotsakul; Paul Turner; Li Yang Hsu
Journal:  Front Microbiol       Date:  2021-11-26       Impact factor: 5.640

5.  Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenic Escherichia coli ST1193 in Vietnam.

Authors:  Quynh Nguyen; To Thi Nguyen Nguyen; Phuong Pham; Vinh Chau; Lan Phu Huong Nguyen; Toan Duc Nguyen; Tuyen Thanh Ha; Nhi Thi Quynh Le; Duong Thuy Vu; Stephen Baker; Guy E Thwaites; Maia A Rabaa; Duy Thanh Pham
Journal:  Microb Genom       Date:  2021-12

6.  Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome.

Authors:  Didem Torumkuney; Subhashri Kundu; Giap Van Vu; Hoang Anh Nguyen; Hung Van Pham; Praveen Kamble; Ngoc Truong Ha Lan; Nergis Keles
Journal:  J Antimicrob Chemother       Date:  2022-09-06       Impact factor: 5.758

7.  Case-based surveillance of antimicrobial resistance in the ACORN (A Clinically Oriented Antimicrobial Resistance Surveillance Network) study.

Authors:  H Rogier van Doorn; Elizabeth A Ashley; Paul Turner
Journal:  JAC Antimicrob Resist       Date:  2020-03-12

8.  Improving antimicrobial use through antimicrobial stewardship in a lower-middle income setting: a mixed-methods study in a network of acute-care hospitals in Viet Nam.

Authors:  Vu Thi Lan Huong; Ta Thi Dieu Ngan; Huynh Phuong Thao; Nguyen Thi Cam Tu; Truong Anh Quan; Behzad Nadjm; Thomas Kesteman; Nguyen Van Kinh; H Rogier van Doorn
Journal:  J Glob Antimicrob Resist       Date:  2021-10-01       Impact factor: 4.035

9.  Plasmid analysis of NDM metallo-β-lactamase-producing Enterobacterales isolated in Vietnam.

Authors:  Aki Hirabayashi; Koji Yahara; Satomi Mitsuhashi; So Nakagawa; Tadashi Imanishi; Van Thi Thu Ha; An Van Nguyen; Son Thai Nguyen; Keigo Shibayama; Masato Suzuki
Journal:  PLoS One       Date:  2021-07-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.